Xu, Yi <br/><br/>
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jul 2006 
 - 4072-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-06-0184  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3-Oxo-5-alpha-Steroid 4-Dehydrogenase--genetics<br/>5-alpha Reductase Inhibitors<br/>Administration, Oral<br/>Animals<br/>Azasteroids--chemistry<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Chromatography, Liquid--methods<br/>Dihydrotestosterone--administration & dosage<br/>Disease Models, Animal<br/>Dutasteride<br/>Enzyme Activation--drug effects<br/>Enzyme Inhibitors--administration & dosage<br/>Finasteride--administration & dosage<br/>Gene Expression Profiling<br/>Humans<br/>Male<br/>Mass Spectrometry--methods<br/>Mice<br/>Mice, Nude<br/>Molecular Conformation<br/>Prostatic Neoplasms--drug therapy<br/>Protein Isoforms--antagonists & inhibitors<br/>RNA, Messenger--antagonists & inhibitors<br/>Rats<br/>Reverse Transcriptase Polymerase Chain Reaction--methods<br/>Structure-Activity Relationship<br/>Xenograft Model Antitumor Assays